Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
SARS-COV-2 SPIKE PROTEIN VARIANT, PHARMACEUTICAL COMPOSITION AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/138648
Kind Code:
A1
Abstract:
The present invention belongs to the field of biomedicine, and relates to a SARS-CoV-2 spike protein variant, a pharmaceutical composition and the use thereof. Specifically, the present invention relates to an isolated polypeptide having an amino acid sequence as shown in any one of SEQ ID NOs: 1-27. The polypeptide of the present invention can simulate broad-spectrum neutralizing antibodies against existing different COVID-19 variant strains, and has a good protection effect on both a SARS-CoV-2 prototype strain and variant strain.

Inventors:
YUAN QUAN (CN)
WU YANGTAO (CN)
WANG SHAOJUAN (CN)
ZHANG YALI (CN)
WEI MIN (CN)
WANG KAI (CN)
WANG ZIKANG (CN)
XIAO JIN (CN)
ZHANG TIANYING (CN)
ZHANG JUN (CN)
XIA NINGSHAO (CN)
Application Number:
PCT/CN2023/073084
Publication Date:
July 27, 2023
Filing Date:
January 19, 2023
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
UNIV XIAMEN (CN)
XIAMEN INNOVAX BIOTECH CO LTD (CN)
International Classes:
C07K14/165; A61K39/215; A61P31/14; C07K19/00; C12N5/10; C12N15/50; C12N15/63
Foreign References:
US10953089B12021-03-23
CN113336832A2021-09-03
Other References:
GOBEIL SOPHIE M.-C., JANOWSKA KATARZYNA, MCDOWELL SHANA, MANSOURI KATAYOUN, PARKS ROBERT, MANNE KARTIK, STALLS VICTORIA, KOPP MEGA: "D614G Mutation Alters SARS-CoV-2 Spike Conformation and Enhances Protease Cleavage at the S1/S2 Junction", CELL REPORTS, ELSEVIER INC, US, vol. 34, no. 2, 1 January 2021 (2021-01-01), US , pages 108630, XP093080135, ISSN: 2211-1247, DOI: 10.1016/j.celrep.2020.108630
Attorney, Agent or Firm:
CCPIT PATENT AND TRADEMARK LAW OFFICE (CN)
Download PDF: